LSD1 has been suggested to be a key therapeutic target in various cancers via its demethylase activity against both histone (i.e., mono- and di-methylated histone 3, lysines 4 and 9), and non-histone targets (e.g., FOXA1), and several LSD1 inhibitors are currently under different stages of clinical trials for the treatment of cancer [20,21]. This evidence concerns the gene FOXA1 and cancer.